+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hormone Sensitive Prostate Cancer Drugs Market - Global Forecast 2025-2030- Product Image
Hormone Sensitive Prostate Cancer Drugs Market - Global Forecast 2025-2030- Product Image
Sale

Hormone Sensitive Prostate Cancer Drugs Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6131640
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The hormone sensitive prostate cancer therapeutics market is changing rapidly as pharmaceutical developers, healthcare providers, and policymakers align around new treatment regimens. Senior decision-makers must navigate evolving innovations, regulatory shifts, and market forces affecting access and economic sustainability in this dynamic landscape.

Market Snapshot: Hormone Sensitive Prostate Cancer Therapeutics

With a growing population of aging patients affected by hormone sensitive prostate cancer, the market is experiencing notable transformation. Breakthroughs in molecular understanding and second generation therapies are reshaping patient care pathways, while shifts in healthcare policies and reimbursement highlight the importance of strategic adaptation. This report offers a comprehensive view for executives seeking to strengthen their competitive position and anticipate forthcoming industry changes.

Scope & Segmentation

  • Drug Classes: Androgen receptor inhibitors—first and second generation; androgen synthesis inhibitors; GnRH agonists; GnRH antagonists.
  • Modes of Administration: Oral and parenteral formulations, including intramuscular and subcutaneous injections.
  • End Users: Hospitals, retail pharmacies, and specialty clinics.
  • Distribution Channels: Hospital pharmacy, online pharmacy, retail pharmacy, wholesalers, and distributors.
  • Therapy Lines: First, second, and third lines of intervention.
  • Patient Age Groups: 65 years and above; under 65 years.
  • Reimbursement Types: Non reimbursed or out-of-pocket and reimbursed.
  • Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, and others), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, and more).
  • Companies Studied: Pfizer Inc., Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Astellas Pharma Inc., Myovant Sciences Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Dr. Reddy's Laboratories Limited.

Key Takeaways for Hormone Sensitive Prostate Cancer Therapeutics

  • Second generation androgen receptor inhibitors deliver greater receptor specificity and have expanded the range of therapeutic options, offering improved safety profiles for diverse patient subpopulations.
  • Expedited regulatory pathways are accelerating the timeline from early clinical data to commercial availability, supporting innovation and early adoption of new agents.
  • Digitally enabled adherence programs and telehealth services are deepening insights into long-term patient outcomes, especially in remote or underserved regions.
  • Supply chain resilience initiatives and diversified sourcing strategies are emerging as critical responses to global trade uncertainties and changing reimbursement frameworks.
  • Corporate strategy trends include robust investment in lifecycle management, cross-sector collaborations, and digital health integration to enhance patient engagement.
  • Regional market disparities and tailored reimbursement models highlight the importance of aligning product positioning with local policy and infrastructure realities.

Tariff Impact on Market Strategies

Revised US tariff structures in 2025 significantly influence the cost and supply chain dynamics of hormone sensitive prostate cancer drugs. Increased duties on imported raw materials and pharmaceutical ingredients are prompting manufacturers to reevaluate sourcing and cost-management strategies. Distributors and wholesalers are adjusting their pricing and logistics models, which may affect product margins. These tariff changes are driving companies towards greater supply chain diversification, transparency in value chain costs, and collaborative risk mitigation, ensuring continued availability and managed affordability in the face of evolving trade regulations.

Research Methodology & Data Sources

The report utilizes a robust blend of primary and secondary research. Primary insights stem from interviews with oncologists, regulatory experts, and supply chain managers, supplemented by expert panel discussions. Secondary analysis includes peer-reviewed journals, regulatory filings, company reports, and clinical trial registries. Data triangulation enhances reliability, ensuring conclusions reflect the complex, multi-dimensional nature of the hormone sensitive prostate cancer therapeutics ecosystem.

Why This Report Matters

  • Delivers actionable, evidence-based insights for R&D, clinical development, and commercialization strategies in hormone sensitive prostate cancer therapeutics.
  • Enables executive leadership to anticipate regulatory, technological, and competitive shifts, supporting well-informed strategic and operational decisions.
  • Guides market entry planning and regional product adaptation by synthesizing complex segmentation, reimbursement, and regional policy considerations.

Conclusion

This report empowers senior decision-makers to navigate the hormone sensitive prostate cancer therapeutics market’s evolving landscape. Executives are equipped to align scientific innovation, operational agility, and stakeholder collaboration to create sustained value and improve patient outcomes.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of next-generation androgen receptor inhibitors with unique binding mechanisms to overcome resistance
5.2. Emergence of novel combination therapies pairing AR antagonists with PARP inhibitors to enhance efficacy
5.3. Adoption of biomarker-driven treatment protocols including genomic profiling for personalized therapy
5.4. Increasing use of radioligand therapy targeting PSMA alongside hormonal treatments for improved outcomes
5.5. Development of oral selective androgen receptor degraders offering improved safety and convenience over injectables
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hormone Sensitive Prostate Cancer Drugs Market, by Drug Class
8.1. Introduction
8.2. Androgen Receptor Inhibitors
8.2.1. First Generation
8.2.2. Second Generation
8.3. Androgen Synthesis Inhibitors
8.4. GnRH Agonists
8.5. GnRH Antagonists
9. Hormone Sensitive Prostate Cancer Drugs Market, by Mode Of Administration
9.1. Introduction
9.2. Oral
9.3. Parenteral
9.3.1. Intramuscular Injection
9.3.2. Subcutaneous Injection
10. Hormone Sensitive Prostate Cancer Drugs Market, by End User
10.1. Introduction
10.2. Hospitals
10.3. Retail Pharmacies
10.4. Specialty Clinics
11. Hormone Sensitive Prostate Cancer Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
11.5. Wholesalers & Distributors
12. Hormone Sensitive Prostate Cancer Drugs Market, by Therapy Line
12.1. Introduction
12.2. First Line
12.3. Second Line
12.4. Third Line
13. Hormone Sensitive Prostate Cancer Drugs Market, by Patient Age Group
13.1. Introduction
13.2. 65 Years And Above
13.3. Under 65 Years
14. Hormone Sensitive Prostate Cancer Drugs Market, by Reimbursement Type
14.1. Introduction
14.2. Non Reimbursed Or Out Of Pocket
14.3. Reimbursed
15. Americas Hormone Sensitive Prostate Cancer Drugs Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Hormone Sensitive Prostate Cancer Drugs Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Pfizer Inc.
18.3.2. Johnson & Johnson
18.3.3. AbbVie Inc.
18.3.4. AstraZeneca plc
18.3.5. Astellas Pharma Inc.
18.3.6. Myovant Sciences, Inc.
18.3.7. Teva Pharmaceutical Industries Ltd.
18.3.8. Sun Pharmaceutical Industries Ltd.
18.3.9. Viatris Inc.
18.3.10. Dr. Reddy's Laboratories Limited
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET: RESEARCHAI
FIGURE 30. HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 31. HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET: RESEARCHCONTACTS
FIGURE 32. HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN SYNTHESIS INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN SYNTHESIS INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY GNRH AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY GNRH AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY GNRH ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY GNRH ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY WHOLESALERS & DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY WHOLESALERS & DISTRIBUTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY 65 YEARS AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY 65 YEARS AND ABOVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY UNDER 65 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY UNDER 65 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY NON REIMBURSED OR OUT OF POCKET, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY NON REIMBURSED OR OUT OF POCKET, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSED, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSED, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 115. CANADA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 116. CANADA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 117. CANADA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 118. CANADA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 119. CANADA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 120. CANADA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 121. CANADA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 122. CANADA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 123. CANADA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. CANADA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. CANADA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. CANADA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. CANADA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 128. CANADA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 129. CANADA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 130. CANADA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 131. CANADA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2018-2024 (USD MILLION)
TABLE 132. CANADA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2025-2030 (USD MILLION)
TABLE 133. MEXICO HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 134. MEXICO HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 135. MEXICO HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 136. MEXICO HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 137. MEXICO HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. MEXICO HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. MEXICO HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 140. MEXICO HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 141. MEXICO HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. MEXICO HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. MEXICO HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. MEXICO HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. MEXICO HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 146. MEXICO HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 147. MEXICO HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 148. MEXICO HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 149. MEXICO HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2018-2024 (USD MILLION)
TABLE 150. MEXICO HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2025-2030 (USD MILLION)
TABLE 225. GERMANY HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 226. GERMANY HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 227. GERMANY HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 228. GERMANY HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 229. GERMANY HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 230. GERMANY HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 231. GERMANY HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 232. GERMANY HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 233. GERMANY HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. GERMANY HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. GERMANY HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. GERMANY HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. GERMANY HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 238. GERMANY HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 239. GERMANY HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 240. GERMANY HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 241. GERMANY HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2018-2024 (USD MILLION)
TABLE 242. GERMANY HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2025-2030 (USD MILLION)
TABLE 243. FRANCE HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 244. FRANCE HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 245. FRANCE HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 246. FRANCE HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 247. FRANCE HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. FRANCE HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. FRANCE HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 250. FRANCE HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 251. FRANCE HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. FRANCE HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. FRANCE HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. FRANCE HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. FRANCE HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 256. FRANCE HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 257. FRANCE HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 258. FRANCE HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 259. FRANCE HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2018-2024 (USD MILLION)
TABLE 260. FRANCE HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT TYPE, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA HORMONE SENSITIVE PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA HORM

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Hormone Sensitive Prostate Cancer Drugs market report include:
  • Pfizer Inc.
  • Johnson & Johnson
  • AbbVie Inc.
  • AstraZeneca plc
  • Astellas Pharma Inc.
  • Myovant Sciences, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Dr. Reddy's Laboratories Limited

Related Topics

Related Reports

Prostate Cancer Therapeutics Market - Global Forecast 2025-2030 - Product Image

Prostate Cancer Therapeutics Market - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Hormone Sensitive Advanced Prostate Cancer Market - A Global and Regional Analysis: Focus on Drug Class, Treatment, and Region - Analysis and Forecast, 2025-2035 - Product Image

Hormone Sensitive Advanced Prostate Cancer Market - A Global and Regional Analysis: Focus on Drug Class, Treatment, and Region - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Metastatic Hormone Refractory Prostate Cancer - Pipeline Insight, 2025 - Product Image

Metastatic Hormone Refractory Prostate Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • 450 Pages
  • Global
From
Prostate Cancer Drugs Market Report 2025 - Product Image

Prostate Cancer Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Enzalutamide Soft Capsules Market - Global Forecast 2025-2030 - Product Image

Enzalutamide Soft Capsules Market - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.